Eosinophilic granulomatosis with polyangiitis after treatment with dupilumab

Kai Yamazaki; Takafumi Nomizo; Kazuhito Hatanaka; Naoki Hayama; Tsuyoshi Oguma; Koichiro Asano

doi:10.1016/j.jacig.2022.03.006

Eosinophilic granulomatosis with polyangiitis after treatment with dupilumab

J Allergy Clin Immunol Glob. 2022 Apr 30;1(3):180-182. doi: 10.1016/j.jacig.2022.03.006. eCollection 2022 Aug.

Authors

Kai Yamazaki¹, Takafumi Nomizo², Kazuhito Hatanaka³, Naoki Hayama¹, Tsuyoshi Oguma¹, Koichiro Asano¹

Affiliations

¹ Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Kanagawa, Japan.
² Department of Medicine, Shonan-Atsugi Hospital, Kanagawa, Japan.
³ Department of Pathology, Tokai University School of Medicine, Kanagawa, Japan.

Abstract

Eosinophilic granulomatosis with polyangiitis (EGPA) in association with the use of asthma medications has been reported. We report the first Asian case of EGPA developed after dupilumab administration in a 77-year-old Japanese woman and discuss the association between dupilumab and EGPA.

Keywords: Dupilumab; eosinophilic granulomatosis with polyangiitis; severe asthma.

Publication types

Case Reports